Die Kombination von T-DXd und Sotorasib zeigte in präklinischen Studien zu KRAS-G12C-mutiertem nicht-kleinzelligem Lungenkrebs vielversprechende Wirksamkeit – Oncodaily
Die Kombination von T-DXd und Sotorasib zeigte in präklinischen Studien bei nicht-kleinzelligem Lungenkrebs mit KRAS-G12C-Mutation eine vielversprechende Wirksamkeit.
Vollstaendiger Artikelinhalt
T-DXd Plus Sotorasib in KRAS G12C-Mutant NSCLC showed durable preclinical tumor regressions and highlighted HER2 testing gaps. , ADCs, Antibody drug conjugates, HER2, HER2 expression, HER2 IHC, KRAS G12C, KRAS G12C-mutant NSCLC, KRAS inhibitor resistance, Lung cancer, NSCLC, OncoDaily Lung, Precision Oncology, preclinical oncology, Sotorasib, T-Dxd, targeted therapy, Thoracic Oncology, Trastuzumab deruxtecan, xenograft models
Produits lies a cet article
Ces produits ont ete automatiquement associes au titre, au resume et au contenu de l article.
Questions frequentes
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Sotorasib – Acheter en ligne SOTOLDX Sotorasib 120 mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.